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Abstract  
Undifferentiated connective tissue disease (UCTD) was first defined by Leroy over 30 years ago. 
UCTD is described as an autoimmune disease which presents similarly to other rheumatic 
diseases but fails to meet laboratory requirements which indicate a specific disease such as 
rheumatoid arthritis, systemic lupus erythematous, Sjogren's or scleroderma.  Common signs and 
symptoms manifested by patients with UCTD include arthralgias, myalgias, fatigue, fever, 
Raynaud’s phenomenon and sicca like symptoms in addition to having a positive antinuclear 
antibody (ANA) test.  Often patients with these symptoms are referred to rheumatology. 
Unfortunately, there is a shortage of rheumatology providers across the nation.  Although 
patients with UCTD have limited access to rheumatologists, there may be room for primary care 
providers to safely and adequately treat their symptoms with the use of disease modifying 
antirheumatic drugs (DMARDs) such as hydroxychloroquine. Evidence exists from recent 
studies that support the use of DMARDs, NSAIDs and low dose corticosteroids in UCTD 
patients to improve arthralgias, myalgias, fever, and functional limitations. Although the research 
indicates that the majority of rheumatologists and primary care providers feel UCTD patients 
should be referred to rheumatology, there is some evidence that primary care providers can also 
initiate and manage the treatment of UCTD patients.  In the absence of rheumatology, primary 
care providers familiar with using DMARDs such as hydroxychloroquine can safely and 
effectively provide treatment for these patients.      
Keywords:  Arthritis, Undifferentiated Connective Tissue Disease, Undifferentiated Systemic 
Rheumatic Disease, Inflammatory Joint Disease, Disease Modifying Anti-Rheumatic Drugs, 
hydroxychloroquine. 
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Treatment of Undifferentiated Connective Tissue Disease with csDMARD’s through Primary 
Care Providers in the Absence of Intervention via Rheumatology 
 Undifferentiated connective tissue disease (UCTD) is a form of autoimmune disease 
which affects the adult population.  Other terms for UCTD include incomplete lupus 
erythematosus, undifferentiated systemic rheumatic disease, latent lupus, and potential lupus. (Al 
Daabil, 2014).  Rheumatology provides treatment to patients diagnosed with arthritic conditions 
and other autoimmune and inflammatory conditions, such as rheumatoid arthritis, Sjogren's 
syndrome, scleroderma and systemic lupus erythematosus. (Layton, 2015).  Unfortunately, by 
2025, data suggests that there will be a projected shortage of rheumatologists by 50% which will 
likely cause strain to the health care sector. (Basen, 2016). Subsequently, patients with UCTD 
face considerable wait times in pursuit of a consultation with a rheumatologist. West and West 
(2014) pointed out that this has emerged as problematic because early pharmacological 
intervention remains the standard of care for the majority of rheumatic disease patients. 
The disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine, are 
provided to patients with UCTD, systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA) and have been found to be effective. (West & West, 2014). Patients with these types of 
clinical and laboratory findings are often referred to rheumatology for consultation.  Primary care 
providers play an essential part in early recognition and referral for patients presenting with 
UCTD. Unfortunately, a shortage of rheumatology providers exists across the nation.  Shortages 
often result in rheumatology clinics screening patient referrals leading them to frequently accept 
only those patients who have laboratory findings which indicate a specific rheumatic disease 
such as RA or SLE.  
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The focus of this scholarly project is to review the available literature to determine 
whether intervention provided by primary care can effectively improve the symptoms of the 
UCTD patients treated with the csDMARD hydroxychloroquine.  The projected outcome is that 
treatment of patients with UCTD using hydroxychloroquine in the primary care setting can 
decrease pain and functional impairment in the absence of rheumatology intervention.  
Statement of the Problem 
Primary care providers deal with a multitude of diseases and illnesses that are difficult to 
accurately diagnose. Often, patients display symptoms that are similar to certain diseases yet 
laboratory findings do not support the suspected condition.  For instance, UCTD is one of the 
arthritis-related diseases with symptoms that are similar to other illnesses, yet laboratory findings 
do not point to any one particular rheumatic disease.  Unfortunately, there is a shortage of 
rheumatologists to attend to the patients suffering from UCTD. (Bazsó et al., 2015).   An article 
written by Ryan Basen in 2016 describes a study done by the American College of 
Rheumatology in 2015 which projected a decline in rheumatology labor force from 4,497 full-
time equivalents to 3,455.  The study projected a shortage of 4,729 rheumatologists by 2030.  
Additionally, 50% of the rheumatology workforce is expected to retire in the next 15 years which 
further limits patient’s access to rheumatologists. (Basen, 2016). Consequently, the UCTD 
patients who do not have access to rheumatologists frequently look to their primary care 
providers for treatment. Nonetheless, it is not clear whether it is possible to decrease the inherent 
symptoms of UCTD by offering early interventions using csDMARDs such as 
hydroxychloroquine via a primary care provider.  The use of csDMARDs by rheumatologists has 
the potential to control rheumatic diseases, but the problem for UCTD patients is the lack of 
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access to timely treatment by rheumatology.  Delaying treatment may result in ongoing 
symptoms such as but not limited to arthralgias, myalgias, and functional impairment. 
Research Question 
In the absence of rheumatology, can primary care providers effectively initiate and 
appropriately manage patients with UCTD using conventional synthetic disease modifying 
antirheumatic drugs, such as hydroxychloroquine, to reduce patient’s symptoms and functional 
impairment? 
Research Methods 
An online databases search was carried out to complete this scholarly project. This 
scholarly project used current research findings related to interventions used for treating UCTD 
and the role primary care providers play in that treatment. Scopus, ScienceDirect, PubMed 
Central (PMC), and ResearchGate were searched to provide scholarly and peer-reviewed articles 
related to the treatment of UCTD patients with csDMARDs in primary care as part of early 
intervention. There were a number of search terms used to identify specific articles on UCTD 
treatment options and role of primary care in the management of connective tissue disease. 
Search terms used included interventions used with UCTD, treatment of UCTD patients in 
primary care, undifferentiated systemic rheumatic disease, early arthritis, the use of with 
csDMARD for UCTD treatment, and effects of early intervention of UCTD using csDMARDs. 
All article publications were written between 1999 and 2017, in English, and free to download 
were included in this literature review.  The relevant themes are clinical presentation of UCTD, 
the prevalence of UCTD, treatment options for UCTD, prescription methods for UCTD, and 
primary care's role in managing UCTD.  Frequently, undifferentiated connective tissue disease 
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was interrelated with undifferentiated systemic rheumatic disease.  This often led to searches 
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Clinical and Serological Presentation of Undifferentiated Connective Tissue Disease 
 A wide array of physical findings can accompany a patient who presents to the clinic 
with signs and symptoms of UCTD.  Some of these include but are not limited to arthralgias, 
Raynaud's syndrome, sicca syndrome, peripheral neuropathy, fatigue, vasculitis, malar rash, 
uraturia, alopecia, oral/nasal lesions, and muscle weakness.   
In 1980, Dr. Leroy, a rheumatologist at Department of Medicine, Medical University of 
South Carolina, first identified undifferentiated connective tissue disease.  At that time several 
studies began to look further into the disease.  In 1999, Mosca et al. completed a systematic 
review of the current research data regarding the criteria in which a provider could use to 
diagnose a patient with undifferentiated connective tissue disease.  With this data, Mosca et al. 
(1999) proposed criteria for undifferentiated connective tissue disease which included (a) signs 
and symptoms suggestive of a connective tissue disease, but not fulfilling the criteria for any 
defined connective tissue diseases (CTD), (b) positive antinuclear antibody (ANA); (c) a disease 
duration of at least one year, including early UCTD.  Although the criteria was established in 
1999, Bortoluzzi et al. (2017) found the classification criteria played a significant role in 
identifying 392 patients with UCTD to be used in a long term study.  
Likewise, Conti et al. (2010) found Mosca et al. (1999) criteria to be useful as well in 
their study of UCTD patients.  In addition to the criteria outlined in Mosca’s 1999 study, they 
found several other clinical features which many UCTD patients had in common. The authors 
identified 41 patients with early UCTD and followed them over a three year period.  They found 
the majority of their patients had more than 3 or 4 clinical symptoms simultaneously.  Most 
prevalent of the clinical manifestations included fatigue (83%), Raynaud’s syndrome (61%), 
arthralgias (56%), muscle pains (56%), fever (51%), and polyarthritis (51%) (Table 1).  A 
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positive ANA and elevated ESR were the most frequent immunological findings.  The study 
showed mild changes in the clinical manifestation over a period of three years, but none were 
statistically significant (p Value>0.05) except for erythema nodosum (p Value <0.05).  However, 
the study was limited by its small sample size.   
In 2004, Mosca et al. completed a review of thirteen existing UCTD studies which looked 
at a total of 1714 patients.  The data was used to compile a profile of UCTD patients.  The profile 
suggested a UCTD clinical course which includes Raynaud’s phenomenon, sicca symptoms, 
arthralgias, arthritis and mucocutaneous manifestations such as photosensitivity, malar rash, and 
oral aphthous ulcers as well as a positive ANA.  They determined that these disease 
manifestations and a positive ANA should be present at least three years.   Additionally, these 
patients demonstrate no major organ involvement. Interestingly, the authors initially reported the 
UCTD symptoms should be present for at least one year to exclude transitory illnesses but then 
concluded at the end of their literature review that the symptoms and serological data should be 
present for at least three years.  This was different than Mosca et al. (1999) criteria which stated 
that the symptoms had to be present for one year only.    
 A multicenter study by Danieli et al. (1999) researched 165 Italian patients diagnosed 
with UCTD ranging in ages from 14-70 years old from ten different clinics. They found that 
UCTD patients commonly presented with arthralgia, mucocutaneous abnormalities and 
Raynaud’s phenomenon.  The Danieli et al. (1999) study, also found evidence of a higher rate of 
major end organ damage to include kidneys, lungs, and heart than previously identified.  This is 
opposite of the findings of Mosca et al. 2004, in which no end organ damage was identified.  
While Danieli et al. (1999) study revealed physical findings that were suggestive of UCTD and 
appeared to indicate possible specific autoimmune disease, laboratory findings did not always 
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match physical findings.  For example, the study found that although patients may have had a 
positive rheumatoid factor (RF), the patients did not always have joint involvement.  
Additionally, some patients were found to have positive anti-SSA/Ro and anti-SSB/La antibody 
but did not present with sicca symptoms. The study found that physical symptoms with non-
specific immunologic abnormalities, otherwise known as UCTD, may ultimately develop into a 
specific connective tissue disease. The Danieli et al. (1999) study was strengthened by the large 
sample size involved in the study.   
 An article by Jessica Berman, MD, specializing in rheumatology at the Hospital for 
Special Surgery, offers clear insight into the relationship of UCTD and with other 
signs/symptoms of other well-known autoimmune diseases using a diagram (Figure 1).   It 
highlights how there is much overlap SLE, Scleroderma and RA symptoms with UCTD making 
UCTD challenging to diagnose and treat.  Although clinically, the patient presentation may 
appear to be directed at a specific diagnosis, lab data does not support clinical findings.       
Prevalence of Undifferentiated Connective Tissue Disease 
 Prevalence of UCTD is difficult to determine as many symptoms are vague which often 
leads to under-reporting or misclassification of UCTD.  Additionally, laboratory results do not 
support a specific diagnosis which also can be frustrating for patient and provider alike. Often 
diagnosing UCTD takes many years.  An article in Autoimmunity Reviews done by Doria et al. 
(2010) illustrated the difficulty in determining the onset of UCTD.  Figure 2 demonstrates the 
progressive nature of the disease which also highlights the difficulty in identifying subclinical 
SLE or UCTD prevalence.  
In 1999, Mosca et al. published a study of existing literature which determined that 
between 20%-52% of patients seen by a rheumatologist with a connective tissue disease may 
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have undifferentiated connective tissue disease.  This range of patients is likely due to the 
variable criteria used to diagnose UCTD.  Mosca et al. (1999) study proposed criteria for 
classification UCTD which is used today (Table 2). The study determined antinuclear antibodies 
must be present, along with a disease duration of at least three years. It also suggested that 
patient’s symptoms and ANA lasting less than three years be classified as having early UCTD. In 
the study by Mosca et al. (2004), it was determined that the disease should have a duration of at 
least three years.  Secondary to the criteria and classification, the prevalence of UCTD remains 
difficult to determine in the general population.  The authors of the study found the absence of 
validated and internationally accepted criteria for UCTD resulted in a limited survey of the 
existing literature at that time.  This remained consistent eleven years later with the study done 
by Doria et al. (2010) which highlighted the challenges of diagnosing UCTD.   
Like many other connective tissue diseases, UCTD patients are predominantly middle-
aged females. (Conti et al., 2010).  Additional findings within the study concluded that after 
three years of follow up, 52% of patients with diagnosed with UCTD maintained this diagnosis 
while 27% demonstrated a clinical regression and 21% progressed to a defined connective tissue 
disease such as SLE or RA.  (Conti et al., 2010). The author’s study was limited secondary to 
that it was observational only and follow up was limited to three years.  
Al Daabil et al. (2014) collected retrospective data on patients seen at Brigham and 
Women’s Hospital Lupus Center between 1 January 1992 and 31 December 2012. Bivariable 
analyses and multivariable logistic regression models were used to analyze the data.  They found 
that of the 264 “potential lupus” patients followed over 20 years in a rheumatology clinic, only 
21% were diagnosed with SLE (per ACR criteria) at the end of 6.3 years.  Of the remaining 
patients, 18% were diagnosed with another disease such as RA, Sjogren’s, and mixed connective 
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tissue disease while 56% were still considered to have “potentials SLE” otherwise known as 
undifferentiated connective tissue disease.  The study was strengthened by its study of a large 
population over a period of greater than six years and contained well documented clinical data.  
A retrospective study by Bortoluzzi et al. (2017) reviewed the charts of 392 UCTD 
patients which were referred to their rheumatology clinic.  The patients were selected using the 
criteria set by Mosca et al. 1999.  They found that patients who presented with acute or subacute 
skin rash, inflammation of the serous tissue and positive antiphospholipid antibodies were the 
most likely to progress to SLE. Of the 283 patients originally classified as having UCTD, over 
the 15 year period 260 patients continued to be classified as having stable UCTD while 23 
patients were eventually diagnosed with SLE.  The study used 2012 Systemic Lupus 
Collaborating Clinics (SLICC) criteria to classify patients as having SLE (Table 3).  This was an 
important aspect of Bortoluzzi et al. (2017) study due to the number of overlapping symptoms of 
UCTD and SLE.  Using the more sensitive SLICC classification criteria for SLE, this increased 
the number of SLE diagnoses which were otherwise labeled as “stable” UCTD.   The study by 
Bortoluzzi et al. (2017) was strengthened by its large population, and its lengthy duration yet was 
limited by its retrospective design.   
A review of the literature by Mosca et al. (2011), suggested that 20% of newly referred 
patients to rheumatology may fall within the undifferentiated profile excluding rheumatoid 
arthritis.  After surveying numerous studies, they concluded that the majority of UCTD patients 
were female (80-99%) and age of disease onset ranged from 32-44 years of age.  After much 
review, they found that of those presenting with UCTD symptoms, up to 70% may remain 
undifferentiated.  Although, this can be identified as stable UCTD authors suggested the 
importance that these patients be monitored for possible disease progression.  The percentage of 
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patients which remained undifferentiated in Mosca et al. (2011) study was 70% which was 
considerably different than the Conti et al. (2010) in which only 52% of patients remained 
undifferentiated.  
 In studying the prevalence of UCTD, as with many other autoimmune diseases, Danieli et 
al. (1999) found that UCTD predominately affects females over males (12:1).  They found that 
the majority of those affected began having significant symptoms in their 40’s.  The study 
suggested that a screening tool or scoring system could further help to identify those patients 
with UCTD. Likewise, Mosca et al. (2011) expressed some difficulty in determining the 
prevalence of UCTD and suggested adding exclusion criteria which could further help identify 
disease onset.  
Prescriptive Treatment Methods for Undifferentiated Connective Tissue Disease 
Data presented by Mosca et al. (2004) indicated that most UCTD patients were 
adequately treated by using low dose corticosteroids (53%) and hydroxychloroquine (11%).  
Additional studies conducted over time by Mosca et al. (2012) saw an increase in antimalarial 
use and rare use of immunosuppressive drugs in treating UCTD patients.  Treatment consisted of 
low-dose corticosteroids (36%) and antimalarial drugs (52%) while 16% of UCTD patients were 
not being treated with prescription medications. 
Conti et al. (2010) concluded that close follow up and use of hydroxychloroquine, 
NSAIDs, and low dose corticosteroids was sufficient to maintain UCTD in an inactive status.  
The treatment regime allowed for control disease activity which included reduction of 
arthralgias, functional limitations, myalgias and fever in many of their case study patients.  
Unfortunately, the study could not determine if a moderately aggressive form of therapy could 
prevent the evolution of the disease.  However, the study did show that the prescriptive therapies 
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offered positive results concerning arthralgias, functional limitations, myalgias, and fever.  The 
authors suggested early UCTD patients have strict follow up at least every six months.  They 
also recommended clinical and diagnostic testing before starting treatment and during follow-up.   
A study of 130 military service members was done by James et al. (2007) in which 
serological, demographic and clinical manifestations data was collected on soldiers with non-
organ damaging early lupus.  The main focus of the study was to see if progression from early 
lupus to SLE was delayed by treatment with hydroxychloroquine, prednisone, or ibuprofen.  
Patients treated with hydroxychloroquine before being diagnosed with SLE had a statistically 
significant increase (p = 0.018) in the time between the symptom onset and SLE diagnosis 
compared to patients who were not treated with hydroxychloroquine before diagnosis (median 
time: 1.08 versus 0.29 years). (James, 2007).  Additionally, the study showed using prednisone 
with UCTD delayed the development of SLE.  The research appeared to indicate that the use of 
hydroxychloroquine and prednisone may have a synergistic effect and prove to be more 
beneficial in delaying the onset of SLE.  The study was limited by the fact that it was not a 
randomized trial and that the natural evolutional history of untreated possible SLE was unknown. 
The study would suggest that a more aggressive approach to treating non-organ early lupus with 
nontoxic hydroxychloroquine is warranted.    
Puchner et al. (2016) carried out a study of Australian rheumatologists and general 
practitioners to measure the perceptions of the general practitioners and rheumatologists 
concerning the issue of the prescribing techniques for connective tissue disease. When 
concerning single or multi-joint inflammatory arthritis 1,215 of the general practitioners (100%) 
and 101 of the rheumatologists (92%) recommended lab tests before referring to a 
rheumatologist.  With regards to connective tissue disease, 78% of general practitioners and 90% 
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of rheumatologists recommended referral to a rheumatologist even if the patient did not show 
signs of joint inflammation.  When treating inflammatory rheumatic disease, 43% of general 
practitioners would always prescribe glucocorticoids, yet only 11% of rheumatologist were in 
favor of general practitioners prescribing glucocorticoids before to referral at all (p<0.001).  
Additionally, 32% of rheumatologists discouraged general practitioners from prescribing 
glucocorticoids as the medication may mask disease symptoms. (Puchner et al., 2016). Overall, 
rheumatologists and general practitioners agree that only rheumatologists should initiate 
treatment using conventional synthetic disease-modifying drugs (DMARDs) such as 
hydroxychloroquine when treating rheumatic diseases, yet one-third of both also agreed that 
when rheumatology availability is limited, then csDMARDs could also be initiated by a general 
practitioner. (Puchner et al., 2016).  
Smolen (2013) found that Target-to-Treat (TTT) approach in treating inflammatory 
rheumatic disease, specifically rheumatoid arthritis, via the use of DMARD was effective in 
improving the health and patient's outcomes.  Smolen (2013) found using TTT (Figure 3) 
resulted in high response rates treating with DMARD plus glucocorticoid use.  Often time’s 
inflammatory disease activity is reflected with complaints of joint pain, fatigue, mucocutaneous 
irritations, etc. Up to 40% of patient with active disease complaints who have a normal CRP, 
ESR, and RF at disease onset. (Sokka et al., 2009).  Disease activity can easily be assessed by 
using the RAPID3 questionnaire which is free online. This could be used by primary care 
providers to monitor disease activity allowing for treatment modifications during follow up 
visits.     
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Role of Primary Care in the Management of Undifferentiated Connective Tissue Disease 
 In the absence of rheumatologists, primary care providers play a crucial role in the 
management of suspected connective tissue disease and other rheumatic diseases. Badley, 
Canizares, Gunz, and Davis (2015) studied the significance of accessing primary care physicians 
when managing inflammatory rheumatic connective tissue disease, especially in the absence of 
rheumatologists. The multi-level study was conducted in Ontario, Canada. The findings indicated 
that the visits to physicians for any form of inflammatory joint pain remained at 130.4 per 1,000 
population, compared to rheumatologists who were 13.4 per 1,000 population. (Badley et al., 
2015).  Thus, 10.3% of the patients made at least one visit to primary care for inflammatory 
arthritis. The findings further showed that most patients with low socioeconomic status or those 
living in areas with limited access to primary care physicians were less likely to have office visits 
to rheumatologists.  Badley et al. (2015) showed that the median geographic availability index of 
rheumatologists indicated that 11 out of the 105 health planning areas located had no availability 
for a rheumatologist. In spite of skewed access to a rheumatologist, 75% of the population lived 
near a facility with a rheumatology department. The findings demonstrated that patients with 
limited access to physicians in the primary care setting are severely affected by the illness 
compared to those living within access areas.  Additionally, primary care providers were less 
likely to use csDMARDs to treat connective tissue disease symptoms.  
 Puchner et al. (2016) established that DMARD treatment in primary care was imperative 
because unnecessary referrals of patients diagnosed with rheumatic condition increased the work 
overload in rheumatology practices.  Badley et al. (2015) noted that adequate patient access to 
rheumatologists was critical because early treatment of early connective tissue disease with 
DMARDs and biologic agents improved clinical outcomes. Moreover, the use of DMARDs and 
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biologic agents improved a patient’s quality of life, functional status, reduced sick leave and 
decreased job loss.  Delayed treatment initiation of DMARDs therapy has the potential to result 
in poor outcomes according to James et al. (2007). Although disease-modifying therapy is not 
commonly initiated in primary care by primary care physicians, DMARDs are recommended, 
especially when timely access to rheumatologists is limited. On the other hand, timely access to 
rheumatologists can significantly reduce joint pain, swelling, global pain, morning stiffness, 
functional status, and improve symptom control.   
Discussion 
Current literature suggests that primary care providers play a significant role in UCTD 
treatment because they are frequently the only and first point of contact for many patients. 
Puchner et al. (2016) and Badley et al. (2015) identified the role of primary care providers to be 
significant in treating early connective tissue disease due to the rheumatology shortage.  James el 
al. (2007) also found this to be true.  Therefore, it may be up to the primary care physicians to 
make use of their clinical knowledge to establish a treatment regimen to meet patient's needs. 
Moreover, even when primary care physicians referred patients with UCTD, to rheumatologists 
in known shortage areas, the referral may be denied as the rheumatologists are frequently 
overwhelmed with treating known rheumatic diseases. Thus, a shortage of rheumatologists has 
resulted in long wait times in the healthcare setting for rheumatology visits. Yet Puchner et al. 
(2016) found that the primary consensus between rheumatologists and general practitioners is 
that a patient must be referred to a rheumatology expert to seek the necessary treatment. 
Similarly, a small percentage of the primary care physicians acknowledged having initiated 
DMARD therapy, but the majority of general practitioners pointed out that they would prescribe 
DMARDs. 
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Moreover, early identification and treatment of UCTD by a primary care provider can 
result in a decline in disease progression, pain, possible joint destruction and functional 
impairment when compared to delayed intervention via rheumatology.  Studies reviewed for this 
project indicated that possible delays in referrals to rheumatology resulted in long-term harm, 
including joint inflammation and destruction.  Primary care providers can initiate treatment with 
DMARDs in the absence of treatment provided through rheumatology.  Using csDMARDs are 
effective in the treatment of UCTD which can lead to improving a patient’s quality of life.  
However, the reviewed literature indicates that primary care physicians will commonly continue 
to use DMARDs, although only a minority initiate them. Discomfort in prescribing DMARDs is 
linked with difficulties in accessing rheumatology referrals in primary care. Early administration 
of DMARD can improve the painful symptoms of UCTD and possibly reduce the progression of 
the disease from UCTD to a definitive connective tissue diagnosis.  Limitations to early 
treatment by primary care providers would include the providers comfort level and knowledge of 
DMARD therapy use. 
The literature on health outcomes for patients receiving care from rheumatologists 
compared primary care providers have supported the need for referrals. Timely consultation with 
a specialist can result in the initiation of medications and improved symptom control. The current 
literature has established that early use of DMARDs is common in primary care, but 40% of 
those primary care physicians who prescribe DMARDs reported that delayed initiation is 
suitable. Thus, this approach of 'wait and see' indicates a primary care physician’s lack of 
urgency in the aggressive treatment of UCTD and may result in delayed referral to a 
rheumatologist.   
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Overall, the current studies have provided significant data supporting the use of 
DMARDs in treating UCTD, but there is minimal evidence that supports the use of DMARDs by 
primary care providers.  Although there have been numerous studies siting criteria used to 
diagnose UCTD, no specific studies were found indicating how confident primary care providers 
are in diagnosing and treating the disease.  Additionally, data indicates that rheumatologists 
overwhelmingly feel that it is the role of rheumatology providers to diagnose and initiate 
treatment of connective tissue disease.  Studies show that in some cases of stable disease, it may 
be appropriate for primary care providers to continue with DMARD use.  In searching for data, 
no studies were found indicating adverse patient outcomes nor positive patient outcomes in cases 
where primary care providers took the lead in diagnosing and treating UCTD with DMARDs.  
After a comprehensive review of the available and current literature, the role of the primary care 
provider in initiating treatment for these patients remains unclear.  It can be surmised that the use 
of DMARDs is likely based in each providers comfort level and knowledge of DMARDs in 
treating UCTD.  Future studies on the use of DMARDs by primary care providers in treating 
UCTD is recommended.   
Applicability to Clinical Practice  
Adequate patient access by patients to rheumatologists is critical because early treatment 
of connective tissue disease via DMARDs provides the opportunity to intervene and improve 
quality of life.  Current literature has established that the use of csDMARD result in low disease 
activity and improve remission rates. On the other hand, delays treatment with DMARDs is 
linked to worse outcomes such as poor health and depression. Thus, in clinical practice, these 
findings are necessary as they can be used to encourage primary care providers to initiate 
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disease-modifying therapy in cases where timely access to rheumatologists is limited.  
Subsequently, negative outcomes can be reduced, and health of patients with UCTD improved.   
Given the gap and lack of accessibility to rheumatologists by patients with UCTD, health 
care sector could collaborate with primary care providers to offer formal training to improve 
patients' outcomes and reduce instances of joint pain, debility, decreased quality of life and 
depression. As recommended by Solomon et al. (2014), rheumatology organizations may put into 
consideration the possibility of working with physician assistant programs and schools of nursing 
to integrate rheumatology into the curriculum. Subsequently, primary care providers frequently 
have the first contact with patients and therefore could be in a position to provide services 
offered by rheumatologists. The presence of primary care providers skilled in rheumatology can 
reduce waiting times in rheumatology outpatient practices and clinics. Subsequently, earlier 
diagnosis and earlier incorporation of therapy could be realized thus leading to better patient 
outcomes. Additionally, delays in consulting a general practitioner, waiting times for 
appointments, delays in referral to a rheumatologist, and delays in identifying a correct diagnosis 
by rheumatology-trained personnel after referral could be improved.  
Early intervention using csDMARDs offered by primary care providers can improve the 
symptoms of UCTD patients.  Primary care providers have an opportunity to greatly impact the 
progression and detrimental effects of UCTD using early csDMARDs therapy.  Education can be 
used to increase knowledge and awareness which can improve access to safe and timely 
treatment. (Brennan-Olsen et al., 2017). The majority of primary care physicians are 
uncomfortable with the identifying and managing UCTD with DMARDs, but recommendations 
by clinical organizations could improve the confidence.  Future directions for research that 
focuses on UCTD care improvement may include altering the design of educational programs for 
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primary care providers such that they have greater comfort prescribing DMARDs. (Gerneau et 
al. 2012).  There continues to be a need for improving awareness and education regarding 
diagnosing and treating UCTD patients in primary care where early treatments with DMARDs 
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Tables and Figures 
Figure 1:  UCTD Overlap 
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Table 1: Clinic Features of UCTD 
Clinical Features % Patients 
Fatigue 83 
Raynaud’s syndrome 61 
Arthralgia 56 





Weight loss 24 
Thyroiditis 19 






Erythema nodosum 9 
Other  7 
 
Conti, V., Esposito, A., Cagluiuso, M., Fantauzzi, A., Pastori, D., Mezzaroma, I., Aiuti, F. (2010). 
Undifferentiated Connective Tissue Disease-An Unsolved Problem: Revision of 
Literature and Case Studies. International Journal of Immunopathology and 
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Table 2:  Suggested preliminary classification criteria for UCTD. 
1. Signs and symptoms suggestive of a connective tissue disease, but not fulfilling the criteria for 
any of the defined CTDs for at least three years. 
2. Presence of antinuclear antibodies determined on two different occasions. 
* If the disease duration is less than three years, patients may be defined as having an early 
undifferentiated connective tissue disease (EUCTD).  
Mosca, M., Neri, R., Bombardieri, S. (1999). Undifferentiated connective tissue diseases 
(UCTD): a review of the literature and a proposal for preliminary classification criteria. 
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Figure 2: Autoantibodies Related to Onset of Diagnosis 
 
Doria, A., Zen, M., Canova, M., Bettio, S., Bassi, N., Nalotto, L…& Iaccarino, L., (2010). SLE 
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Figure 3:  Target to Treat- Generic Model 
 
Solomon, D. H., Yelin, E., Katz, J. N., Lu, B., Shaykevich, T., & Ayanian, J. Z. (2013). Treatment 
of rheumatoid arthritis in the Medicare Current Beneficiary Survey. Arthritis Research & 
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Table 3: 2012 SLICC Classification Criteria for SLE 
 
Petri, M., Orbai, A.-M., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., … Magder, L. S. 
(2012). Derivation and Validation of Systemic Lupus International Collaborating Clinics 
Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatism, 
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